Related Experiment Video
Updated: Jun 24, 2026
Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
Published on: September 22, 2023
Peroxisome proliferator-activated receptor gamma negatively regulates allergic rhinitis in mice
Naoko Fukui1, Kohei Honda, Eiko Ito
1Department of Sensory Medicine, Division of Otorhinolaryngology Head and Neck Surgery, Akita University, School of Medicine, Akita, Japan.
Background:
Peroxisome proliferator-activated receptor gamma(PPAR-gamma) has been shown to play an important role in the control of inflammatory responses acting on macrophages, mast cells, T cells, and eosinophils. The present study was aimed at investigating the effects of PPAR-gamma agonist on nasal symptoms and eosinophil accumulations in nasal mucosa by using a murine allergic rhinitis model. Furthermore, we examined the expression of PPAR-gamma in the nasal mucosa in mice.
Methods:
BALB/c mice were sensitized and challenged intranasally with ovalbumin. Ciglitazone, a PPAR-gamma agonist, was administered orally 6 hours before each nasal challenge.
Results:
Administration of PPAR-gamma agonist significantly decreased the number of nasal rubs, nasal histamine responsiveness, serum IgE, IL-5 production from the spleen, and eosinophilic infiltration in the nasal mucosa. Furthermore, PPAR-gamma was expressed in eosinophils and epithelial cells in the nasal mucosa by immunohistochemistry.
Conclusions:
PPAR-gamma was expressed in eosinophils and epithelial cells in the nasal mucosa. Also, the oral administration of ciglitazone is effective in upper airway allergic inflammation in mice.
Insights
The PPAR-gamma agonist ciglitazone effectively reduced allergic rhinitis symptoms and eosinophil infiltration in a mouse model. This study confirms PPAR-gamma expression in nasal tissues, highlighting its therapeutic potential for upper airway inflammation.
Area of Science:
- Immunology
- Pharmacology
Background:
- Peroxisome proliferator-activated receptor gamma (PPAR-gamma) modulates inflammatory responses in various immune cells.
- PPAR-gamma plays a role in controlling inflammation in conditions like allergic rhinitis.
Purpose of the Study:
- To investigate the therapeutic effects of a PPAR-gamma agonist on nasal symptoms and eosinophil accumulation in a murine model of allergic rhinitis.
- To examine the expression of PPAR-gamma within the nasal mucosa of mice.
Main Methods:
- A murine model of allergic rhinitis was established using ovalbumin sensitization and intranasal challenge.
- BALB/c mice were administered the PPAR-gamma agonist, ciglitazone, orally before nasal challenges.
Main Results:
- PPAR-gamma agonist treatment significantly reduced nasal rubs, histamine responsiveness, and serum IgE levels.
- Reduced IL-5 production and eosinophilic infiltration in the nasal mucosa were observed.
- Immunohistochemistry confirmed PPAR-gamma expression in nasal eosinophils and epithelial cells.
Conclusions:
- PPAR-gamma is expressed in key cellular components of the nasal mucosa, including eosinophils and epithelial cells.
- Oral administration of ciglitazone demonstrated efficacy in mitigating upper airway allergic inflammation in mice.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
02:06Allergic Reactions
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...